Pharmaceutical companies and industry groups have urged the FDA to provide additional details on when a single pivotal trial plus confirmatory evidence is sufficient to support approval of a new drug. The request centers on practical examples and clearer decision frameworks for sponsors planning registrational strategies. The push reflects ongoing tension between traditional multi-trial evidence expectations and newer pathways that could reduce development timelines—especially for conditions where larger randomized trial programs may be difficult. Industry is seeking more predictability in how “one pivotal” strategies will be assessed. The advocacy also underscores how guidance language can materially affect biotech planning, including trial design choices, endpoints selection and the use of external or real-world data as confirmatory support.